



Study Designs and Quantitative Tools in Rare and Life-Threatening Brain Tumor

Guest Editor:

Dr. Wonsuk Yoo
Ivy Brain Tumor Center, Phoenix,
AZ 85013, USA

Deadline for manuscript
submissions:
closed (20 October 2024)

Message from the Guest Editor

Dear Colleagues,

Glioblastoma is a rare, life-threatening, and highly difficult to cure disease. It has shown high failure in phase 3 glioblastoma trials, even though previous phase 2 trials showed promising efficacy. There may be a need for earlier studies to become more reliable and for the use of evidence-based quantitative tools to overcome the disconnection from phase 2 to phase 3 trials. This disconnection could be occurring for several reasons: design restriction of preclinical studies and differences between animals and human, traditional single-arm trials in phase 2 trials in GBM, and the surrogate of progression-free survival of phase 2 trials for overall survival in phase 3 trials. With the recent advancements in technology and programming languages, we are able to utilize these new technologies to develop novel study designs using quantitative tools.

Dr. Wonsuk Yoo
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)